drugset

drugset / Trial / NCT02785185

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185 ↗

Phase 2 Completed 150 enrolled Bausch Health Americas, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.

Timeline

Start: 2016-06
Primary completion: 2016-12-02
Completion: 2017-01

Publications

Kerdel FA, Draelos ZD, Tyring SK, Lin T, Pillai R. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis. J Dermatolog Treat. 2019 Jun;30(4):333-339. doi: 10.1080/09546634.2018.1523362. Epub 2018 Nov 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	halobetasol propionate	Small molecule	0.01 %	Topical
Subject	halobetasol propionate	Small molecule	0.05 %	Topical

Indications